Failure to Monitor for Hypoglycemia and Hyperglycemia in Residents Receiving Insulin
Summary
The facility failed to monitor the signs and symptoms of hypoglycemia and hyperglycemia for two residents who were receiving insulin. Resident 34 was admitted with diagnoses including type 2 diabetes mellitus with diabetic chronic kidney disease, acute on chronic diastolic congestive heart failure, and end stage renal disease. The care plan identified the resident as being at risk for hypoglycemia and hyperglycemia and directed staff to observe for symptoms such as polyuria, polydipsia, polyphagia, changes in level of consciousness, blurred vision, profuse sweating, irritability, and tremors, but the MAR for May and June 2026 did not show monitoring for these signs and symptoms while the resident was receiving Novolog FlexPen as sliding scale insulin. Resident 57 was admitted with diagnoses including type 2 diabetes mellitus with foot ulcer, COPD, neuralgia, and neuritis. The resident’s care plan and physician orders identified a risk for hypoglycemia and hyperglycemia and included monitoring for symptoms such as confusion, dizziness, shakiness, irritability, hunger, pale skin, sweating, trembling, weakness, anxiety, headache, poor coordination, coma, polyuria, polydipsia, blurred vision, profuse sweating, irritability, and tremors. The order summary also included Trulicity and Novlin R sliding scale insulin, and the MDS indicated the resident received insulin injections, but the MAR for May and June 2026 did not document monitoring for these signs and symptoms. During interviews, LVN 1 stated that residents receiving insulin should have monitoring for signs and symptoms of hypoglycemia and hyperglycemia and that this was not done for either resident. The DON stated that when residents had orders for insulin, monitoring for hypoglycemia and hyperglycemia should be done and documented on the MAR, and that both conditions could result in serious illness and/or death. The facility’s policies on insulin administration and diabetes clinical protocol also addressed monitoring and notification related to hypoglycemia and hyperglycemia.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.